(Q43951950)

English

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

0 references

1 reference

based on heuristic

inferred from title

Parkinson's disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

0 references

author name string

W H Poewe

1

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

G Deuschl

2

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

A Gordin

3

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

E-R Kultalahti

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

M Leinonen

5

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Celomen Study Group

6

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

language of work or name

0 references

publication date

1 April 2002

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Acta Neurologica Scandinavica

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

105

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

245-255

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Success and problems of long-term levodopa therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

21 January 2018

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

21 January 2018

New selective COMT inhibitors: useful adjuncts for Parkinson's disease?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

21 January 2018

General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

21 January 2018

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

21 January 2018

Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

21 January 2018

Health-related quality-of-life measurement in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

21 January 2018

Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

21 January 2018

The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

21 January 2018

Levodopa motor complications in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

21 January 2018

Twelve-month safety of entacapone in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

21 January 2018

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

21 January 2018

Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

21 January 2018

Treatment of Parkinson's disease: Problems with a progressing disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Costs of drug treatment in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0404.2002.1O174.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1034/J.1600-0404.2002.1O174.X

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43951950&oldid=2104603758"